Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16024890.
- Also identified by PMC identifier 1739743.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous disorder and both clinical course and response to treatment vary widely. Because of the propensity for relapse, CIDP requires maintenance therapy after the initial response to treatment. There is no consensus regarding this in the published literature. A patient with CIDP was treated with oral prednisolone and cyclophosphamide pulse therapy but required repeated plasma exchange and intravenous immunoglobulin (IVIg). Treatment with ciclosporin freed the patient from repeated IVIg administration. Therapeutic responses in 14 subsequent cases including three patients who showed improvement with ciclosporin are also presented along with an algorithm of the authors' suggested protocol for treatment. Ciclosporin should be considered for patients with intractable CIDP who require repeated IVIg.
Medical subject headings
- Antirheumatic Agents
- Cyclosporine
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating